《40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"》
HIMS 估值偏低、具备上行潜力；其平台模式可从任何胜出的 GLP-1 药物中获取价值，随着市值增长，做空压力将逐步减弱。
我想谈谈“Hems & Hers Health”这家公司。这是另一个备受关注的名称，尤其是在社交媒体上。它是一只波动较大的股票，但似乎正处于过渡阶段，我很想知道你对它在这个领域所扮演角色的看法，以及你对这家公司的总体看法。
I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .